| |
Media
Room - News Release
CONTACT: Geri
M. Berdak
The Solae Company
gberdak@solae.com
ARNOLD JOINS THE SOLAE COMPANY AS PRESIDENT AND CEO
Former DuPont Ag and Nutrition Vice President Succeeds Tanda
ST. LOUIS, June 03, 2003 – The Solae Company today announced
that Tony L. Arnold has joined the company as president and CEO
following the resignation of Stephan B. Tanda. Arnold was previously
vice president of Marketing for DuPont Corporation’s Ag and
Nutrition business.
“We are very pleased to welcome Tony. He is well-regarded
throughout the organization. His background in general management
and marketing will help us immensely as The Solae Company accelerates
the marketing of our many plant-based proteins to developers of
a wide range of consumer products,” said Erik Fyrwald, chairman.
“At the same time, we are grateful for Stephan’s many
contributions to our organization, and wish him well,” Fyrwald
added.
The company noted that Erik Fyrwald, vice president of DuPont’s
Nutrition and Health operations, will continue to serve as chairman
of The Solae Company’s board of directors.
The Solae Company, based in St. Louis, Missouri, serves food and
beverage manufacturers, dietary supplement developers, retailers
and consumers in 100 countries worldwide, including the United States
and Canada, Europe and the Middle East, Latin America and the Asia/Pacific
region. The Solae Company provides its more than 3,000 customers
with more than a thousand different products, including many brands
that are widely recognized in the food ingredients industry: Alpha®,
Danpro®, Samprosoy®, Centrolex®, Promine®, Procote®,
Supro®, Proplus®, and Solae™ and its sub-brands.
The company was formed earlier in 2003 through an alliance between
Bunge Limited (NYSE: BG) and DuPont (NYSE: DD). The company’s
business is focused on significantly growing the global business
in plant-based, specialty food ingredients, initially addressing
soy protein and lecithin, and expanded offerings of products and
services that help customers compete and prosper.
# # #
|
|
|
|